Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe 10:47:47 2024-06-17 am EDT 5-day change 1st Jan Change
984.3 DKK -0.68% Intraday chart for Novo Nordisk A/S -0.23% +41.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novo Nordisk CEO to Testify on High Prices of Ozempic, Wegovy in US Senate Hearing MT
Weight-loss options for US youth are hard to come by RE
Novo Nordisk CEO Agrees to US Senate Committee Testimony to Address 'Outrageously High' Ozempic, Wegovy Prices MT
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy RE
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup DJ
Novo Nordisk: study results for hemophilia A CF
NOVO NORDISK : Deutsche Bank reiterates its Buy rating ZD
Second Chinese drugmaker seeks approval for Ozempic generic RE
Employer coverage for weight-loss drugs rises sharply, survey finds RE
IVivani Medical Gets FDA Clearance to Start Trial of GLP-1 Implant for Diabetes DJ
Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan MT
Global markets live: Apple, Oracle, Amazon, Boeing, Tesla... Our Logo
Health Care Down as Rally Pauses -- Health Care Roundup DJ
Sector Update: Health Care Stocks Softer Late Afternoon MT
Novo Nordisk to Face Senate Panel Subpoena Vote Over Ozempic, Wegovy Prices MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon MT
Sector Update: Health Care MT
Novo Nordisk President to Face Senate Panel Subpoena Vote Over Ozempic, Wegovy Prices MT
US Senate Committee to Subpoena Novo Nordisk Inc. President Over Prices of Diabetes, Obesity Drugs MT
Senate Committee to Vote June 18 to Subpoena Novo Nordisk President Doug Langa MT
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices RE
Dsm-firmenich sees boost as weight-loss drugs spur healthier choices RE
Argus Research Raises Novo Nordisk Price Target to $160 From $125, Maintains Buy Rating MT
Added health benefits of Wegovy, Zepbound could attract more men, doctors say RE
Novo Nordisk braces for Ozempic rivals in China RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991 DKK
Average target price
934.3 DKK
Spread / Average Target
-5.72%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Sector Update: Health Care Stocks Advance Late Wednesday Afternoon